Filtered By:
Condition: Ischemic Stroke
Therapy: Statin Therapy

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 1639 results found since Jan 2013.

Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey
Conclusion The EUROASPIRE III stroke-specific module shows that secondary prevention and risk factor control in patients after ischaemic stroke need to be improved in four European centres at the time of the study since about half of patients are not achieving risk factor targets defined in European guidelines.
Source: European Journal of Preventive Cardiology - September 11, 2015 Category: Cardiology Authors: Heuschmann, P. U., Kircher, J., Nowe, T., Dittrich, R., Reiner, Z., Cifkova, R., Malojcic, B., Mayer, O., Bruthans, J., Wloch-Kopec, D., Prugger, C., Heidrich, J., Keil, U. Tags: Original scientific paper Source Type: research

Early High-dosage Atorvastatin Treatment Improved Serum Immune-inflammatory Markers and Functional Outcome in Acute Ischemic Strokes Classified as Large Artery Atherosclerotic Stroke: A Randomized Trial
Abstract: Statins have beneficial effects on cerebral circulation and brain parenchyma during ischemic stroke and reperfusion. The primary hypothesis of this randomized parallel trial was that treatment with 80 mg/day of atorvastatin administered early at admission after acute atherosclerotic ischemic stroke could reduce serum levels of markers of immune-inflammatory activation of the acute phase and that this immune-inflammatory modulation could have a possible effect on prognosis of ischemic stroke evaluated by some outcome indicators. We enrolled 42 patients with acute ischemic stroke classified as large arteries ath...
Source: Medicine - March 1, 2016 Category: Internal Medicine Tags: Research Article: Clinical Trial/Experimental Study Source Type: research

Statins and poststroke intracerebral hemorrhage: Concern but increasing reassurance
Post hoc analyses of data from randomized controlled trials can generate useful hypotheses, but need to be considered exploratory. When conducted, such evaluations should adhere to specified criteria and test for a treatment by subgroup interaction for the trial's primary endpoint.1 The best way to proceed if unexpected but potentially important outcomes occur is less clear. Concern that treatment with HMG-CoA reductase inhibitors (i.e., statins) might increase the risk of poststroke intracerebral hemorrhage (ICH) arose from an unanticipated observation in the Stroke Prevention with Aggressive Reduction in Cholesterol Leve...
Source: Neurology - April 24, 2016 Category: Neurology Authors: Goldstein, L. B., Nederkoorn, P. J. Tags: All Cerebrovascular disease/Stroke, Intracerebral hemorrhage EDITORIALS Source Type: research

Statin Adherence and the Risk of Stroke: A Dose-Response Meta-Analysis
ConclusionImproved adherence to statins was associated with a lower risk of stroke, particularly of IS.
Source: CNS Drugs - March 12, 2017 Category: Neurology Source Type: research

Reduction in High-Sensitivity C-Reactive Protein Levels in Patients with Ischemic Stroke by Statin Treatment: Hs-CRP Sub-Study in J-STARS.
CONCLUSION: In non-cardiogenic ischemic stroke, pravastatin treatment may reduce vascular inflammation as assessed by Hs-CRP, and higher Hs-CRP levels appeared to increase the risk of recurrent stroke and vascular events. PMID: 28302952 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - March 19, 2017 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

Ischemic stroke of the “hand knob area”: A case series and literature review
In conclusion, in this series the most prevalent stroke mechanism was SUE, mainly embolic stroke of undetermined source. The outcome was excellent regardless of stroke mechanism.
Source: Journal of Clinical Neuroscience - March 23, 2019 Category: Neuroscience Source Type: research

Statins in Ischemic Stroke Prevention: What Have We Learned in the Post-SPARCL (The Stroke Prevention by Aggressive Reduction in Cholesterol Levels) Decade?
We describe the current status of lipid-lowering therapies for ischemic stroke prevention. The SPARCL trial published in 2006 has been a landmark study in vascular neurology. The trial demonstrated that high-dose atorvastatin prevents recurrent stroke, and led the AHA/ASA to recommend statin therapy for patients with stroke or TIA of atherosclerotic origin.Recent findingsRecently, the J-STARS study demonstrated that therapy with low-dose pravastatin reduced atherothrombotic infarction incidence among patients with prior ischemic stroke. Besides, several trials have shown improved stroke outcomes with non-statin lipid-lower...
Source: Current Treatment Options in Neurology - April 7, 2019 Category: Neurology Source Type: research

Inpatient statin use and stroke recurrence in patients with or without diabetes mellitus.
Conclusion: Inpatient statin use was associated with lower stroke recurrence in non-diabetic patients after acute ischaemic stroke, but no definite association between inpatient statin use and stroke recurrence in patients with diabetes mellitus was found. PMID: 31328681 [PubMed - as supplied by publisher]
Source: Neurological Research - July 23, 2019 Category: Neurology Tags: Neurol Res Source Type: research

Opportunities for intervention: stroke treatments, disability and mortality in urban Tanzania
ConclusionsThe 90-day mortality of stroke presenting at MNH is 50%, much higher than in higher income settings. Although severe stroke presentations are a major factor, efforts to improve the quality of care and prevent complications of stroke are urgently needed. Acute stroke interventions with low number needed to treat represent challenging long-term goals.
Source: International Journal for Quality in Health Care - August 28, 2018 Category: International Medicine & Public Health Source Type: research

Renal Function-Dependent Associations of Statins with Outcomes of Ischemic Stroke.
CONCLUSIONS: In patients with acute ischemic stroke, the associations of statins with mortality and functional outcomes was dependent on eGFR. PMID: 32418948 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - May 20, 2020 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

A Combination of Atorvastatin and Aspirin Enhances the Pro-Regenerative Interactions of Marrow Stromal Cells and Stroke-Derived Monocytes In Vitro
Conclusion: Atorvastatin, alone and in combination with aspirin can promote anti-inflammatory effect by modulating the secretome profile of Mo and MSCs. Our results suggest that stroke trials involving the use of intravenous MSCs should consider the effect of aspirin and atorvastatin, both of which are administered to the majority of hospitalized ischemic stroke patients.
Source: Frontiers in Pharmacology - April 20, 2021 Category: Drugs & Pharmacology Source Type: research

Characterization of familial hypercholesterolemia in Taiwanese ischemic stroke patients
Aging (Albany NY). 2021 Jul 27;13(undefined). doi: 10.18632/aging.203320. Online ahead of print.ABSTRACTFamilial hypercholesterolemia (FH) is a common genetic disorder characterized by a lifelong elevated low-density lipoprotein cholesterol (LDL-C) level. The relationship between FH and ischemic stroke is still controversial. We enrolled ischemic stroke patients prospectively in our neurological ward, and divided them into two groups according to LDL-C levels with a threshold of 130 mg/dl. Targeted sequencing was performed in all stroke patients for LDLR, APOB, and PCSK9 genes. The fifty-eight high-LDL subjects were older,...
Source: Aging - July 27, 2021 Category: Biomedical Science Authors: Hsin Tung Hsueh-Ju Lin Po-Lin Chen Tsai-Jung Lu Pei-Pei Jhan Jun-Peng Chen Yi-Ming Chen Chen-Chin Wu Yung-Yang Lin Tzu-Hung Hsiao Source Type: research

Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials
CONCLUSIONS AND RELEVANCE: This study suggests that the benefits and risks of more intensive LDL-C-lowering statin-based therapies for recurrent stroke risk reduction might be more favorable than the benefits and risks of less intensive LDL-C-lowering statin-based therapies, especially for patients with evidence of atherosclerosis.PMID:35188949 | DOI:10.1001/jamaneurol.2021.5578
Source: Atherosclerosis - February 21, 2022 Category: Cardiology Authors: Meng Lee Chun-Yu Cheng Yi-Ling Wu Jiann-Der Lee Chia-Yu Hsu Bruce Ovbiagele Source Type: research

Risk Factors for Postischemic Stroke Epilepsy in Young Adults: A Nationwide Population-Based Study in Taiwan
ConclusionsStroke severity, aphasia, malignancy, and drug abuse were associated increased risk of PSE and statin use may protect against PSE in young adults. Reducing the severity of stroke, statin use and controlling unhealthy behaviors might be able to decrease the development of PSE. Since PSE is associated with poor outcomes, early identification or intervention of PSE based on the risk factors might reduce the harmful effects of PSE.
Source: Frontiers in Neurology - May 20, 2022 Category: Neurology Source Type: research